Lumacaftor: all 24 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure PatientsRecruitingNCT07695090Phase 2
- Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment InitiationCompletedNCT04235140Phase 3Results posted
- A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCompletedNCT03625466Phase 2Results posted
- Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508delCompletedNCT03601637Phase 3Results posted
- A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT03125395Phase 3Results posted
- Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR MutationCompletedNCT03061331Phase 2Results posted
- A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationCompletedNCT02875366Phase 4Results posted
- Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With IvacaftorCompletedNCT02544451Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR MutationCompletedNCT02514473Phase 3Results posted
- Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung DiseaseCompletedNCT02390219Phase 3Results posted
- A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic FibrosisCompletedNCT01931839Phase 3Results posted
- Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT01897233Phase 3Results posted
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedNCT01807949Phase 3Results posted
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedNCT01807923Phase 3Results posted
- Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutationCompletedNCT01225211Phase 2Results posted
- Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene MutationCompletedNCT00865904Phase 2Results posted
- Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated TabletsCompletedNCT05968612Phase 1
- Mutation-specific Therapy for the Long QT SyndromeCompletedNCT04581408Phase 2
- Phase 1, QT/QTC Interval Study in Healthy SubjectsCompletedNCT01910415Phase 1
- A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With IvacaftorCompletedNCT01899105Phase 1
- Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy SubjectsCompletedNCT01888393Phase 1
- A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult SubjectsCompletedNCT01768663Phase 1
- Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy SubjectsCompletedNCT01216046Phase 1
- Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy SubjectsCompletedNCT00966602Phase 1